GRANULES.NS

T2Emerging Markets (IEMG)

Granules India Limited

Next est. report · AMC

Loading…
Loading chart…
Key Reported Metrics, Reratings Triggers & Results3 rows

This metric is critical for Granules, reflecting the success of its strategic acquisition of Senn Chemicals and its focus on the high-growth GLP-1 peptide manuf

Upcoming print · 2026-11-05

Key reported metricsRerating thresholds
MetricLast periodWhy it mattersWhat's needed for reratingRerating contextEarnings date
Peptide CDMO Revenue Growth106%

This metric is critical for Granules, reflecting the success of its strategic acquisition of Senn Chemicals and its focus on the high-growth GLP-1 peptide manufacturing theme. Robust growth here validates the company's strategic pivot and future potential in a specialized, high-margin area.

Peptide CDMO Revenue Growth needs to demonstrate significant acceleration, ideally maintaining triple-digit year-over-year growth, and show clear progress towards the mid-plan target of US$50 million revenue with 30%+ margins.

Robust Peptide CDMO growth is critical, validating Granules' strategic pivot into high-growth GLP-1 peptide manufacturing. Sustained strong growth confirms the success of the Senn Chemicals acquisition and future potential in this specialized, high-margin area.

Profit After Tax (PAT)60%

PAT demonstrates Granules' ability to translate revenue growth into bottom-line profitability. It is crucial for investor confidence, especially as the company integrates acquisitions and shifts towards higher-margin complex generics and peptide CDMO businesses.

Profit After Tax (PAT) should show robust double-digit year-over-year growth, ideally exceeding Q1 FY27's PAT of ₹1.80 billion INR, and demonstrate continued margin expansion.

PAT is crucial for investor confidence, reflecting the company's ability to translate revenue into bottom-line profitability. Strong PAT growth, especially with margin expansion, signals effective integration of acquisitions and validates the shift to higher-margin businesses.

Total Revenue22%

This is a fundamental indicator of the company's overall business health and market demand across its diverse product portfolio, including APIs, FDFs, and the growing peptide segment. Strong growth signals effective market penetration and operational execution.

Total Revenue needs to hit at least ₹15.56 billion INR, meeting or exceeding analyst consensus for the upcoming quarter (Q2 FY27), and demonstrate year-over-year growth of 20% or more.

Strong revenue growth validates Granules' market penetration and operational execution across its diversified portfolio. Exceeding consensus confirms the success of its strategic shift towards higher-value products and overall business health, driving a positive rerating.